Improving the economics of NASH/NAFLD treatment through the use of systems biology
Review article, 2017
Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD). We surveyed NASH therapies currently in development, and found a significant variety of targets and approaches. Evaluation and clinical testing of these targets is an expensive and time-consuming process. Systems biology approaches could enable the quantitative evaluation of the likely efficacy and safety of different targets. This motivated our review of recent systems biology studies that focus on the identification of targets and development of effective treatments for NASH. We discuss the potential broader use of genome-scale metabolic models and integrated networks in the validation of drug targets, which could facilitate more productive and efficient drug development decisions for the treatment of NASH.
Author
J. Bosley
Clermont Bosley LLC
C. Boren
Royal Institute of Technology (KTH)
SangWook Lee
Royal Institute of Technology (KTH)
Morten Grötli
University of Gothenburg
Jens B Nielsen
Chalmers, Biology and Biological Engineering, Systems and Synthetic Biology
M. Uhlen
Royal Institute of Technology (KTH)
Jan Borén
University of Gothenburg
Sahlgrenska University Hospital
Adil Mardinoglu
Chalmers, Biology and Biological Engineering, Systems and Synthetic Biology
Drug Discovery Today
1359-6446 (ISSN) 18785832 (eISSN)
Vol. 22 10 1532-1538Subject Categories
Pharmacology and Toxicology
DOI
10.1016/j.drudis.2017.07.005
PubMed
28736156